humans with the early stage CKD. 7 In almost all of these experiments and studies, the amelioration effects of dipyridamole on proteinuria were indicated to be mediated by the repression of platelet aggregation which was generally recognized in CKD.
Dipyridamole increases cAMP levels by inhibiting phosphodiesterase in a variety of cells including platelets. The cAMP acts through three pathways of its downstream: protein kinase A (PKA), exchange factor directly activated by cAMP (Epac), 8 and cyclic nucleotide-gated (CNG) ion channels. 9 In the Epac pathway, the increased intracellular cAMP binds to Epac, a guanine nucleotide exchange factor, followed by activation of the low molecular weight G-protein Rap. Epac contributes to numerous pathophysiological processes, including proliferation, differentiation, cell adhesion, cell junction formation, and exocytosis. In the present study, the effects of dipyridamole against renal fibrosis, the late stage CKD, were investigated in a system without platelet aggregation. In addition, the mechanism by which dipyridamole exerted its effects was examined.
| MATERIALS AND METHODS

| Reagents and cells
H89, a selective PKA inhibitor, was purchased from Sigma-Aldrich 
| Cell culture
NRK49F cells were cultured in D-MEM supplemented with 10% FBS (JRH Biosciences, Lenexa, KS, USA), 100 IU/mL penicillin and 100 μg/mL streptomycin in a humidified 5% CO 2 -95% atmospheric air incubator at 37°C. Throughout this study, cells from passages 3 to 8 were used. Five × 10 4 cells were seeded in 1.5 mL medium with 10% FBS and cultured for 24 hours. After washing, they were preincubated in a serum-free medium for 30 minutes. Then they
were exposed to stimulants and/or inhibitors in the medium with 0.5% FBS.
| Immunofluorescence microscopy
In order to identify the cell type, a monolayer culture of the cells was grown on a two-well Labtek chamber slide (AS ONE, Osaka, Japan). Cell cultures were divided into three groups: the control, the 2 ng/mL TGF-β1, and the 2 ng/mL TGF-β1 + 3 μmol/L dipyridamole group. After treatments, the cells of each group were fixed in 4%
paraformaldehyde and subjected to indirect immunofluorescence labelling for α-SMA. In brief, the cells were permeabilized with 0.5%
Triton X-100 in PBS for 20 minutes, washed with PBS, and incubated with the primary antibody against α-SMA (Sigma-Aldrich, St
Louis, MO, USA; 1:800 dilution) for 2 hours at room temperature (RT). After washing, they were incubated with FITC-conjugated goat anti-mouse IgG secondary antibody (Caltag Laboratories, Burlingame, CA, USA; 1:200 dilution) for 1 hour at RT, followed by DAPI nuclear staining. After staining, the cells were rinsed, observed, and photographed using an Olympus BX 60 microscope equipped with epifluorescence optics. As a negative control, the primary antibody was replaced with mouse nonimmune serum.
| Western blots
The cells were exposed to inhibitors of cAMP pathways, 5 μmol/L H89 or 3 μmol/L ESI-05, and activators of cAMP pathways, 30 μmol/ L Phe-cAMP or 10 μmol/L O-Me-cAMP for 1 hour before the addition of 2 ng/ml TGF-β1. They were exposed to 3 μmol/L dipyridamole for 30 minutes before a treatment of TGF-β1. They were cultured for 48 hours after TGF-β1 was added. Then cell lysates were prepared by adding ice cold protein extraction reagent (modified RIPA) with proteinase inhibitors. They (10 μg protein) were applied by 10% SDS-PAGE electrophoresis and blotted to a polyvinylidene difluoride filter membrane. The membranes were incubated with anti-α-SMA, or anti-GAPDH antibody. The membranes were then incubated with appropriate horseradish peroxidase-conjugated secondary antibodies. Immunoreactive bands were visualized by using the ECL system, and the intensity of the bands was measured by Image Quant TL (GE Healthcare, Buckinghamshire, UK).
| Quantitative real-time PCR
The cell lysates were subjected to RT-PCR for α-SMA at 24 hour after the addition of TGF-β1. Total RNA was isolated from the cells using the RNeasy Mini kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. cDNA was prepared using the Tran- | 1609
| EIA
The amount of intracellular cAMP at 1 hour after addition of dipyridamole was measured by using a cAMP enzyme immunoassay kit from Cayman Chemical according to the manufacturer's instructions.
| Statistics
Quantitative data were compared using Wilcoxon's test or Student's t test of the software package JMP (SAS Institute, Cary, NC, USA). P-values less than 0.05 were considered statistically significant.
F I G U R E 2
Contribution of cAMP pathways to suppressive effects of dipyridamole on α-SMA expression. A, Alteration of cAMP levels in the cytoplasm yielded by dipyridamole. After incubation the lysates of the cells were subjected to EIA of cAMP. Bar graph shows relative intracellular cAMP levels. *P < 0.01 vs control. B, Effect of the inhibitor of PKA or Epac pathway on α-SMA expression. After incubation with the reagents for 48 hours, the cell lysates were subjected to Western blots for α-SMA. Representative Western blots and relative quantification are provided. *P < 0.005 vs control;**P < 0.005 vs TGF-β1 group; NS not significant vs TGF-β1 + dipyridamole group; ***P < 0.01 vs TGF-β1 + dipyridamole group. C, Effect of the activator of PKA or Epac pathway on α-SMA expression. After incubation with the reagents the cell lysates were subjected to Western blots for α-SMA. Representative Western blots and relative quantification of α-SMA are shown. *P < 0.001 vs control; **P < 0.05; ***P < 0.001 vs TGF-β1 group. D, Effect of the inhibitor or the activator of Epac pathway on α-SMA mRNA expression. The cell lysates were subjected to RT-PCR. Bar graph shows relative values of α-SMA mRNA levels normalized to GAPDH signal. *P < 0.01 vs control; **P < 0.05 vs TGF-β1 group; ***P < 0.05 vs TGF-β1 + dipyridamole group
| Results and discussion
Immunofluorescence for α-SMA revealed that TGF-β1 induced, to a large extent, expression of α-SMA forming stress fibre ( Figure 1A ). both the PKA and Epac pathways suppressed fibrosis. 10 However, the PKA activator was shown to attenuate fibrosis yielded by exposure of pulmonary fibroblasts to TGF-β1, while the Epac activator did not affect it. 11 In contrast, it was demonstrated that the PKA activator induced fibrosis by mesangial cells. 12 The different effects between the results of the present study and the findings of these reports might be because of the difference in the cells used. The question of which process of the TGF-β1 signalling pathways did dipyridamole block via Epac pathway activation will be resolved in the next paper.
In conclusion, dipyridamole suppressed TGF-β1-induced α-SMA expression via Epac pathway activation. This protective effect of dipyridamole against fibrosis was not mediated by platelet aggregation and was directly exerted on fibroblasts. The Epac pathway provides a new pharmacological approach of dipyridamole for treatment of fibrosis in CKD.
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